Ascletis Pharma Inc. announced that it has received CNY 700 million in series B round of funding led by existing investor C-Bridge Capital, a fund managed by C-Bridge Capital Partners LLC on January 3, 2017. The transaction involved participation from existing investors Goldman Sachs Group, Merchant Banking Division, Tasly Pharmaceutical Group Co., Ltd. (SHSE:600535), new investors Qianhai Equity Investment FOF, a fund managed by Shenzhen Capital Group Co., Ltd., WTT Investment, and FOCUS Media Jiangnanchun Foundation.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 HKD | -2.94% | +3.12% | -9.59% |
Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.59% | 176M | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
-21.76% | 29.48B | |
+55.51% | 25.43B | |
-14.78% | 15.59B | |
-18.49% | 11.49B | |
-15.61% | 11.1B | |
-44.02% | 11.3B | |
+3.37% | 8.75B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Pharma Inc. announced that it has received CNY 700 million in funding from C-Bridge Capital Partners LLC, Goldman Sachs Group, Merchant Banking Division, Tasly Pharmaceutical Group Co., Ltd., Shenzhen Capital Group Co., Ltd.